Belatacept
- Generic Name
- Belatacept
- Brand Names
- Nulojix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 706808-37-9
- Unique Ingredient Identifier
- E3B2GI648A
- Background
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of t...
- Indication
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Linda Cendales
- Target Recruit Count
- 50
- Registration Number
- NCT02310867
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Belatacept 3 Month Post Transplant Conversion Study
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Lorenzo Gallon
- Target Recruit Count
- 28
- Registration Number
- NCT02213068
- Locations
- 🇺🇸
Northwestern University, The Comprehensive Transplant Center, Chicago, Illinois, United States
Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 57
- Registration Number
- NCT02152345
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Regimen Optimization Study
- Conditions
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT02137239
- Locations
- 🇺🇸
Emory Univeristy, Atlanta, Georgia, United States
🇺🇸University Of Illinois, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Belatacept for Renal Transplant Recipients With Delayed Graft Function
- Conditions
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 8
- Registration Number
- NCT02134288
- Locations
- 🇺🇸
The Ohio State Universtiy Wexner Medical Center, Columbus, Ohio, United States
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT02130817
- Locations
- 🇺🇸
University of Wiscsonsin Hospital and Clinics, Madison, Wisconsin, United States
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 6
- Registration Number
- NCT02103855
- Locations
- 🇺🇸
Indiana University Health, University Hospital, Indianapolis, Indiana, United States
Efficacy of Belatacept in Reducing DSA
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- East Carolina University
- Target Recruit Count
- 3
- Registration Number
- NCT02078193
- Locations
- 🇺🇸
East Carolina University, Greenville, North Carolina, United States
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 20
- Registration Number
- NCT01953120
- Locations
- 🇺🇸
UCLA Kidney Transplant Research, Los Angeles, California, United States
Belatacept Therapy for the Failing Renal Allograft
- Conditions
- Interventions
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Andrew B Adams
- Target Recruit Count
- 13
- Registration Number
- NCT01921218
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.